At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
POAI Predictive Oncology
Market Closed 06-28 16:00:00 EDT
1.04
+0.00
0.00%
盘后1.09
+0.05+4.81%
19:44 EDT
High1.11
Low1.02
Vol39.97K
Open1.04
D1 Closing1.04
Amplitude8.64%
Mkt Cap4.27M
Tradable Cap3.99M
Total Shares4.10M
T/O41.68K
T/O Rate1.04%
Tradable Shares3.84M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.